Ensoma shutters Copenhagen site from its Twelve Bio acquisition

Genomic medicines startup Ensoma is shuttering its Copenhagen site and also eliminating “a very small number” of roles at its Boston office, a spokesperson confirmed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Invenra’s antibody gains FDA designations for neuroblastoma

Invenra’s bispecific antibody is under development to treat neuroblastoma. Credit: Kateryna Kon/Shutterstock. Invenra has received rare pediatric disease designation (RPDD) and orphan drug designation (ODD)

August 26, 2024

Complete Genomics Garners the Prestigious 2023 R&D 100 Awards for Cutting-Edge Innovation

SAN JOSE, CALIFORNIA, 23 August, 2023- Complete Genomics, Inc., a pioneering genomic sequencing company, today proudly received the honor of the R&D 100 Awards from R&D

August 24, 2023

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care | Psychedelic Invest

NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the recruitment of Perth, Australia-based

October 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.